Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horáková, Eva Havrdová, Raed Alroughani, Guillermo Izquierdo Ayuso, Serkan Özakbaş, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, François Grand’Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz, María Trojano, Pamela McCombe, Mark Slee, Jeannette Lechner‐Scott, Recai Türkoğlu, Patrizia Sola, Diana Ferraro, Franco Granella, Julie Prévost, Davide Maimone, Olga Skibina, Katherine Buzzard, Anneke van der Walt, Bart Van Wijmeersch, Tünde Csépány, Daniele Litterio A. Spitaleri, Ostoja Vucic, Romain Casey, Marc Debouverie, Gilles Edan, Jonathan Ciron, Aurélie Ruet, de Sèze, Élisabeth Maillart, Hélène Zéphir, Pierre Labauge, Gilles Defer, Christine Lebrun‐Frénay, Thibault Moreau, Éric Berger, Pierre Clavelou, Jean Pelletier, Bruno Stankoff, Olivier Gout, Éric Thouvenot, Olivier Heinzlef, A. Al-Khedr, Bertrand Bourre, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean‐Philippe Camdessanché, Aude Maurousset, I. Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle, David Laplaud, Nils Koch‐Henriksen, Finn Sellebjerg, Per Soelberg Soerensen, Claudia Pfleger, Peter Vestergaard Rasmussen, Michael Broksgaard Jensen, Jette Lautrup Frederiksen, Stephan Bramow, Henrik Kahr Mathiesen, Karen Schreiber, Melinda Magyari, Sandra Vukusic, Helmut Butzkueven, Tomáš Kalinčík